The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > REGULATORY
REGULATORY
- MHLW Approves Amgen/Astellas’ Evenity, Gilead Sciences’ Epclusa and More
January 9, 2019
- Amendment of PMD Law Will Be Top Priority in 2019: MHLW Bureau Chief Miyamoto
January 8, 2019
- MHLW to Follow Up on Drug Makers’ Efforts to Observe New Detailing Guidelines
January 7, 2019
- Gilead’s Bictegravir, BioCryst’s BCX7353 Get Orphan Status
January 7, 2019
- Orphan Status Given to ReproCELL’s Adipose-Derived Mesenchymal Stem Cell Therapy
December 27, 2018
- MHLW Draft Budget Earmarks 8.99 Billion Yen for Drug-Related Projects
December 26, 2018
- 44 Million Yen Allotted to Fuel Biologics Development: Health Policy Bureau’s FY2019 Budget
December 26, 2018
- Japan OKs FY2019 Budget, Record 34.6 Trillion Yen Earmarked for Social Security
December 25, 2018
- MHLW OKs Add’l Indications for Keytruda, Tecentriq, Hemlibra, and More
December 25, 2018
- After Settling on October 2019 Re-Pricing, When Will Govt Reveal New Drug Prices?
December 21, 2018
- Clarify Definition of Ads to Not Hamper Info Delivery to Patients: PhRMA Tells Govt
December 21, 2018
- CEFP Finalizes Govt Reform Timeline Urging FY2019 Debate on “Economic Evaluations” for Reimbursement Decisions
December 21, 2018
- Approvals for Epclusa, Keytruda’s MSI-H Indication and More Could Be Delayed into 2019
December 21, 2018
- Chuikyo Snubs Industry’s Call to Exclude Listed Products from CEA Scope
December 20, 2018
- PhRMA, EFPIA Pitch Enhanced Appraisal Model for Japan HTA Plan; Chuikyo Reps Acknowledge ICER Limitations
December 20, 2018
- Govt to Pare Drug Prices by 2.4% in October 2019 Ad-Hoc Re-Pricing
December 19, 2018
- MHLW Revises Conditions of Approval for Alecensa Based on Findings from Post-Marketing Survey
December 19, 2018
- MHLW Compiles Proposal for PMD Law Amendment, Eyes Diet Submission of Related Bill Next Year
December 18, 2018
- Ministers Agree on Ad-Hoc Drug Re-Pricing in October 2019, 29 Billion Yen Saving in State Coffers
December 18, 2018
- MHLW Committee on Medical Devices Recommends Approval of 2 Cancer Gene Panel Tests
December 17, 2018
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…